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Abstract 
Corticosteroid (CS) therapy is used widely in the treatment of a range of pathologies, but can delay 
production of myelin, the insulating sheath around central nervous system nerve fibers. The cellular targets 
of CS action are not fully understood, i.e. 'direct' action on cells involved in myelin genesis 
[oligodendrocytes and their progenitors the oligodendrocyte precursor cells (OPCs)] versus 'indirect' action 
on other neural cells. We evaluated the effects of the widely used CS dexamethasone (DEX) on purified 
OPCs and oligodendrocytes, employing complementary histological and transcriptional analyses. 
Histological assessments showed no DEX effects on OPC proliferation or oligodendrocyte 
genesis/maturation (key processes underpinning myelin genesis). Immunostaining and RT-PCR analyses 
show that both cell types express GR (the target for DEX action), ruling out receptor expression as a causal 
factor in the lack of DEX-responsiveness. GRs function as ligand-activated transcription factors, so we 
simultaneously analyzed DEX-induced transcriptional responses using microarray analyses; these 
substantiated the histological findings, with limited gene expression changes in DEX-treated OPCs and 
oligodendrocytes. With identical treatment, microglial cells showed profound and global changes post-DEX 
addition; an unexpected finding was the identification of the transcription factor Olig1, a master regulator of 
myelination, as a DEX responsive gene in microglia. Our data indicate that CS-induced myelination delays 
are unlikely to be due to direct drug action on OPCs or oligodendrocytes, and may occur secondary to 
alterations in other neural cells, such as the immune component. To the best of our knowledge, this is the 
first comparative molecular and cellular analysis of CS effects in glial cells, to investigate the targets of this 
major class of anti-inflammatory drugs as a basis for myelination deficits.  
 
Key words: oligodendrocyte; Olig1; corticosteroid; glucocorticoid receptor; microglia; microarray 
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Introduction  
Corticosteroid (CS) therapy is currently used widely for the treatment of a range of pathologies, but can 
delay myelin genesis during development and repair (remyelination) in major white matter tracts of the 
central nervous system (CNS) including the optic nerve and corpus callosum.
1–7
 Notably, high and multiple 
CS doses are frequently used during periods of developmental myelination,
8,9
 and to treat conditions 
involving myelin injury/repair such as Multiple Sclerosis and spinal cord injury.
10,11
 The cellular 
mechanisms underpinning the reported CS induced defects in myelin genesis are largely unknown, but 
observations that myelination delays occur without accompanying axon loss
2,5
 indicate that such effects may 
be primarily underpinned by glial responses to CS. 
Myelination involves a sequential process: initially, proliferative and migratory precursors called 
oligodendrocyte precursor cells (OPCs) populate the CNS
12
 and receive signals to generate 
oligodendrocytes. Astrocytes are important mediators of myelin genesis, by influencing OPC migration, 
proliferation and differentiation into oligodendrocytes;
13
 the latter engage in complex, intercellular cross-talk 
with axons to generate functional myelin.
14
 Oligodendrocytes continue to generate myelin sheaths well into 
adulthood (about the fifth decade) in the temporal and parietal lobes, with perturbations to this process being 
linked to cognitive decline in Alzheimer's disease.
15
 Following myelin injury, remyelination broadly 
recapitulates developmental myelination, and critically depends on a timed orchestration of cellular and 
molecular events in lesions.
16
 Myelin genesis in the normal and diseased CNS is therefore a complex 
multifactorial process, and studies aiming to establish the cellular targets of CS action during 
myelinogenesis yield contradictory information.
17
 Evidence for direct effects on OPCs includes CS 
treatment of CG4 cells (an OPC line)
18
 and adrenalectomized rats,
19
 where OPC proliferation was inhibited. 
Further, CS have pro-differentiation effects on myelinogenic cells,
20,21
 but in demyelination models CS can 
delay
22
 or enhance
23
 remyelination. These confounding responses may relate to the immunomodulatory 
effects of CS on microglia; the latter remove myelin debris (inhibitory to myelin genesis) and secrete 
stimulatory/inhibitory cytokines that can impact oligodendrocyte development.
24
 However, CS treatment of 
astrocytes can also down-regulate oligodendroglial differentiation factors.
25
 While neurons engage in cross-
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talk with oligodendroglial cells during myelination, one study has reported limited CS effects in striatal 
neurons, suggesting that at least some neurons are not direct targets of CS action.
26
 
Such observations suggest that CS may impact myelination through indirect effects mediated by non-
myelinogenic glial cell intermediaries, but rigorous evaluation of direct effects of CS on oligodendroglia is 
lacking. There is heavy reliance in the field on histological observations in cultures, but the constituent cell 
types are often poorly characterized.
27,28
 In terms of drug action, CS are lipid-soluble, readily entering cells 
where they bind to appropriate cytosolic ligand-activated receptors, with nuclear translocation of complexes 
and action on hormone response elements to regulate the associated genes.
29
 In this context, the critical 
question of whether oligodendrocyte lineage cells express the glucocorticoid receptor (GR) is also not fully 
resolved, with two studies yielding contradictory results.
19,30
  
The widespread clinical use of CS in conjunction with the critical roles of myelin in neuroprotection and 
regulation of electrical conductivity
16
 highlight the need to resolve such conflicting information by defining 
the mechanisms underpinning aberrant myelinogenesis. To address this issue, and specifically, to evaluate if 
CS exert direct effects on oligodendroglial cells, we have employed a two-pronged methodological approach 
comprising histological analyses complemented with parallel transcriptional analyses (as CS effects are 
mediated by transcriptional regulation). We have employed isolated purified cultures, and short time frames 
for the studies, to evaluate direct cellular actions of CS and the potential primary/early targets of drug action 
respectively. We consider this approach necessary to provide comprehensive insights into the mechanisms 
by which CS therapy may impact myelination.  
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Results and Discussion 
To the best of our knowledge, this is the first study to employ a dual methodological approach (that provides 
independent and corroborative readouts of CS effects at the morphological and molecular levels) in order to 
investigate the mechanisms by which this major class of anti-inflammatory drugs may impact myelin 
genesis. The inclusion of independent transcriptional analysis of DEX treated cultures, in conjunction with 
histological assays, provides an unbiased approach unhindered by prior expectation of CS effects on neural 
cells. Further, the use of isolated, purified glial cultures in these experiments allows for examination of 
direct actions of CS which cannot be evaluated within the context of the multicellular lesion environment in 
vivo.
3
 High purity OPC, astrocyte and microglial cultures were generated as judged by staining for cell 
specific markers; values were: 96.4 ± 0.5% A2B5
+
 (n = 6) and 96.9 ± 1.2% NG2
+
 for OPCs (n = 3); 97.8 ± 
0.8% OX42
+
 for microglia (n = 6); and 94.4 ± 1.7% glial fibrillary acidic protein positive (GFAP
+
) for 
astrocytes (n = 3). Highly enriched oligodendrocyte cultures were obtained: 81.2 ± 5.2% myelin basic 
protein positive (MBP
+
; n = 6), with the majority of the remaining cells showing morphological features of 
earlier stages of the oligodendrocyte lineage under phase contrast microscopy; microglial cells (<5%) were 
readily identifiable by their morphologies, and astrocytic morphologies were never observed in these 
cultures. 
Histological analyses indicate that oligodendrocyte lineage cells are unaffected by CS treatment 
In control (untreated and vehicle) and DEX treated cultures, OPCs displayed typical bipolar phenotypes, 
with similar morphologies of A2B5
+
 and NG2
+
 cells observed between treatment groups (Figure 1a-b). No 
DEX effects on OPC proliferation/survival were observed in terms of total number of nuclei per microscopic 
field or percentage of pyknotic nuclei (Figure 1c-d). No differences were found between the groups in terms 
of numbers or percentages of A2B5
+
 or NG2
+
 cells per microscopic field (Figure 1e-h). 
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Figure 1 DEX does not affect the survival, proliferation or antigenic profiles of OPCs. Typical 
fluorescence micrographs (with phase contrast counterparts, inset) showing NG2
+
 OPCs with similar 
staining profiles and morphologies in vehicle control (a) and treated cultures (DEX; 72 h; 1 µM) (b). For 
all treatment conditions, bar graphs illustrate the number of healthy nuclei per microscopic field (c), 
percentage of pyknotic nuclei (d), number of A2B5
+
 (e) and NG2
+
 (f) cells per microscopic field, and the 
percentage of A2B5
+
 (g) and NG2
+
 (h) cells in OPC cultures [72 h DEX; for (c) and (d) n = 6; for (e-h) n = 
3; (a-b) insets, scale bar = 50 µm]. 
To monitor the effects of DEX on oligodendrocyte differentiation, OPC cultures (propagated in OPC-MM 
for 24 h) were switched to Sato differentiation medium and allowed to differentiate +/- DEX for up to 7 
days. Complex process-bearing oligodendrocytes were found in both control and DEX treated 
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oligodendrocyte cultures (Figure 2a-b). No differences were observed between groups in the total number of 
nuclei or the percentage of pyknotic nuclei per microscopic field (Figure 2c-d). Further, using our 
morphological scoring criteria, no CS effects were discernible on oligodendrocyte maturation in terms of the 
extent of process/membrane elaboration (Figure 2g). Therefore, DEX treatment did not affect the survival, 
proliferation, antigenic profiles or morphologies (including extent of differentiation) of oligodendrocyte 
lineage cells. 
 
Figure 2 DEX does not affect the survival or maturation of oligodendrocytes. Typical fluorescence 
micrographs showing MBP
+
 oligodendrocytes with similar morphologies and staining profiles at different 
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stages of differentiation in vehicle control (a) and treated cultures (DEX; 7 d; 1 µM) (b). Note the extensive 
and complex branching of processes in both cultures. For all treatment conditions, bar graphs illustrate the 
number of healthy nuclei per microscopic field (c), percentage of pyknotic nuclei (d), number of MBP
+
 cells 
per microscopic field (e), the percentage of MBP
+
 cells (f) and morphological scoring of MBP
+
 
oligodendrocytes indicating extent of differentiation/maturation (g) in oligodendrocyte cultures (7 d DEX; n 
= 3 for all graphs). 
Positive control cultures: Untreated microglial cultures and those treated with vehicle showed cells with a 
branching ramified morphology (Figure 3a). DEX treatment dramatically reduced cell densities with many 
cells showing a rounded appearance (Figure 3b-c) confirming that the CS preparations used were 
physiologically active, and the spectrophotometrically confirmed doses (see Methods) were appropriate for 
eliciting cellular responses. No significant differences were noted in microglial response to 1 and 100 µM 
DEX, presumably due to saturating concentrations of DEX employed. In this context, the dissociation 
constant (Kd) of GR with DEX is unknown for microglia, but is reported to be 3.5 – 6.0 nM in multicellular 
cultures derived from rat brain.
31-32
 This is greatly exceeded by the lowest DEX dose tested (1 µM), and as 
DEX readily diffuses across the cell membrane,
33
 this supports the concept of receptor saturation.  Further, it 
should be noted that biological responses to DEX in microglia
34
 and other cell types
35-37
 have been shown to 
display similar plateau effects. 
Page 8 of 33
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9 
 
 
Figure 3 DEX dramatically alters numbers and morphologies of microglia. Typical fluorescence 
micrographs (with phase contrast counterparts, inset) showing many process bearing OX42
+
 microglia in a 
vehicle control culture (a) compared with a dramatic reduction in cell numbers and alterations to 
morphology following treatment (DEX; 72 h; 1 µM) (b). (c) Bar graph illustrating the number of OX42
+
 
cells per microscopic field in microglial cultures for all treatment conditions (72 h DEX; *p < 0.05 versus 
untreated control; one-way ANOVA, Bonferroni’s post-test; n = 3). 
 
The absence of CS effects on oligodendrocyte lineage cells cannot be attributed to the absence of GR 
expression 
The lack of an overt oligodendroglial response to CS treatment could be explained by an absence of the 
necessary receptor (GR) expression. Earlier studies report that oligodendroglial lineage cells express GR 
mRNA but evidence for GR expression in rat OPCs/oligodendrocytes has not been definitive. Although 
several studies report GR (mRNA or protein) expression in ‘glial cells’, often poorly characterized cultures 
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are employed in the experiments, leaving doubt regarding cell specific receptor expression and related CS 
effects. For example, Vielkind et al.
28
 show GR expression in “tentatively identified” OPCs in mixed glial 
cultures, without OPC-specific counterstaining (some of these cells were GFAP
+
, suggesting that they are 
astrocytes), while Jung-Testas and Baulieu
27
 employed uncharacterized mixed glial cultures, identifying 
only GFAP
+
 astrocytes and CNP
+
 or MBP
+
 oligodendrocytes, with neither study immunostaining for 
microglia. The unresolved question of oligodendroglial expression of GR was addressed here using 
immunostaining for GR protein and RT-PCR for GR mRNA detection. 
Microglia and astrocytes (the positive controls) expressed GR mRNA (Figure 4a) and immunostained for 
GR protein (Figure 4b-c). Both cytoplasmic and nuclear localization of GR were observed in both cell types. 
Similarly, both detection methods confirmed GR mRNA and protein expression in OPCs and 
oligodendrocytes (Figure 4a, d-e) with a comparable pattern of intracellular distribution of receptor. 
Therefore, we have shown here that all the major glial cell types studied (using well characterized glial 
culture systems) including the oligodendrocyte lineage cells, express both GR mRNA and protein, 
independently validated by PCR and immunocytochemical analyses, confirming their potential to respond to 
CS treatment.  
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Figure 4 All glial cell types express GR mRNA and protein. (a) RT-PCR analyses showing expression by 
all glial cell types of GAPDH mRNA (452 bp product; housekeeping gene) and GR mRNA (216 bp product). 
Central numbers indicate bp values of ladders. Fluorescence micrographs showing GR expression (H300 
and BuGR2 antibodies) in lectin
+
 microglia (b), GFAP
+
 (c) and morphologically-identified astrocytes (c, 
inset), NG2
+
 OPCs (d) and MBP
+
 oligodendrocytes (e). OL = oligodendrocyte. 
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Transcriptional analyses support the concept that oligodendrocyte lineage cells are not primary, direct 
targets of CS action 
Supporting the histological observations, the transcriptional effects following DEX addition were most 
pronounced in microglia and astrocytes (positive controls for CS induced gene expression changes; Figure 
5a-b), where 257 and 38 genes were differentially expressed, respectively. In contrast, the oligodendrocyte 
lineage cells showed modest responses with 5 and 10 differentially expressed genes in OPCs and 
oligodendrocytes, respectively (Figure 5c-d).  
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Figure 5 DEX induced transcriptional changes are extensive in microglia and astrocytes, but limited in 
oligodendroglia. Volcano plots illustrate the transcriptional response to dexamethasone treatment (DEX; 48 
h; 1 µM) detected by microarray analysis of purified microglial (a), astrocyte (b), OPC (c) and 
oligodendrocyte cultures (d). Positive fold change represents upregulation, negative fold change represents 
downregulation (versus vehicle controls; x axis). Dashed horizontal lines represent p < 0.05 (red), p < 0.01 
(blue) and p < 0.001 (green). Note extensive changes in microglia and astrocytes, but limited changes in 
OPCs and oligodendrocytes. (e) Mean normalized expression values (error bars represent 95% confidence 
intervals) for Olig1 showing elevated expression in DEX treated microglia (unpaired t-test; p < 0.05; n = 
3). 
The majority of differentially expressed microglial genes are related to immune function but some individual 
genes of interest were identified. Two such key genes are Olig1 (Figure 5e) a basic helix-loop-helix 
transcription factor involved in the maturation of oligodendrocytes
38
 and oligodendrocyte-myelin 
glycoprotein (Omg ; human homolog known as OMG and OMGP), both upregulated in microglia following 
DEX treatment. The former finding was confirmed using immunostaining to detect Olig1 protein; both 
OPCs and oligodendrocytes (positive controls; Figure 6a-b) expressed Olig1, as did microglial cells (Figure 
6c). In addition, a significant increase in Olig1 expression was evident in DEX treated microglial cultures 
compared to controls (Figure 6d-e). Within each culture, DEX treated microglia consistently demonstrated 
significantly higher optical density values than controls (DEX minus vehicle for each culture; Figure 6f). 
Differentially expressed genes identified in astrocytes treated with DEX were significantly enriched in a 
number of gene ontologies including “response to corticosteroid stimulus” (see Supporting Information, 
Astrocyte.Enrichment_Analysis).  
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Figure 6 Microglia express Olig1 protein, and upregulate Olig1 expression following DEX treatment. 
Fluorescence micrographs showing Olig1 expression in NG2
+
 OPCs (a), MBP
+
 oligodendrocytes (b) and 
lectin
+
 microglia (c; inset shows Olig1counterpart image). (d) Olig1expression in a vehicle control 
microglial culture. (e) Marked increase in microglial Olig1expression following DEX addition (DEX; 48 h; 
1 µM). (f) Bar graph showing normalized mean optical density measurements of Olig1 expression, with 
elevated values in DEX treated microglia over vehicle controls (48 h; 1 µM; paired t-test; p < 0.05; n = 3). 
By contrast, for OPCs no enriched terms were identified which passed our inclusion criteria. For 
oligodendrocytes, a single pathway map “Role of ZNF202 in regulation of expression of genes involved in 
Atherosclerosis” was highlighted by pathway analysis (ZNF202 is a transcription factor; genes in this 
pathway are those encoding HDL proteins and APOE). Multiple gene ontology terms were identified, with 
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the most enriched being “regulation of growth” (genes encoding: HTRA1, HDL proteins, Alpha crystallin B, 
Neuromodulin and APOE) and “response to reactive oxygen species” (genes encoding: Cystatin C, HDL 
proteins, Alpha crystallin B and APOE). Additional terms were also identified for astrocytes and microglia, 
with the full results provided as Supporting Information. Whilst the gene expression changes in 
oligodendrocytes are limited, there were a few changes of note. Both Apoe and Gap43 were downregulated 
in oligodendrocytes on DEX addition. APOE has a major role in lipid metabolism,
39
 but its role in the 
genesis of lipid rich myelin sheaths in the CNS is currently unclear. Gap43 is expressed in immature 
oligodendrocytes but down regulated during maturation
40
 – although we did not detect morphological 
alterations in CS treated oligodendrocytes, we cannot currently rule out alterations in their engagement with 
axons.  
In contrast to OPCs and oligodendrocytes, both astrocytes and microglia showed more global and 
pronounced effects following identical CS treatment. For astrocytes, the affected genes included well known 
glucocorticoid-responsive genes, including Sgk,
41
 Fkbp5
42
 and Tsc22d3 (aka Gilz).
43
 Further, five of the 
affected genes (Sult1a1, Sgk, Ddit4, Klf9 and Tsc22d3) were recently shown to be up-regulated by short-
term (4 h) glucocorticoid treatment of striatal astrocytes,
26
 whereas the most down-regulated gene (Ednrb) 
was also reported to be negatively regulated by glucocorticoids in neural progenitor cells.
44
 Together, these 
observations underscore the validity/robustness of the microarray procedures utilized here. With respect to 
the microglial arrays, an unexpected finding was the identification of the transcription factor Olig1 as a DEX 
responsive gene, given its role as a master regulator of myelination, with expression reported in 
oligodendroglia and radial glia.
45,46
 Nevertheless, immunocytochemical approaches unequivocally 
demonstrated (i) Olig1 expression in cultured microglia, and (ii) up-regulation of protein expression by DEX 
treatment, further validating the sensitivity of the microarray system used here. The implications of this 
finding remain to be established, but do question the prevailing view that Olig1 expression in the CNS is 
restricted to oligodendrocyte lineage cells.  
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It is well established that different tissues/cell types exhibit markedly differing responses to glucocorticoids; 
indeed, glucocorticoid sensitivity can vary throughout the cell cycle within a single cell type.
47
 
Consequently, the finding that the various cell types exhibit differing transcriptional responses to DEX (as 
shown here for the first time with CNS glia) is not without precedent. However, elucidation of the factors 
accounting for the inter-cellular differences — and limited glucocorticoid sensitivity of oligodendroglia, in 
particular — will require extensive further study. For example, whilst all glial cell types express the GR, 
information is lacking regarding the complement of GR isoforms expressed in each cell type. This is 
important because (i) diverse GR subtypes can be generated from the Nr3c1 gene locus (by alternative 
splicing coupled with the usage of alternative translation initiation sites), each subtype being further subject 
to multiple post-translational modifications (including phosphorylation, sumoylation, acetylation and 
ubiquitination), and; (ii) different protein isoforms can exhibit distinct transactivation/transrepression 
patterns of gene regulation.
47-49
 Other factors influencing glucocorticoid action and which may differ 
between glial cell types include: GR chaperones/co-chaperones, transcriptional co-regulators and chromatin 
remodelling complexes;
47
 transcription factors such as AP-1, NF-KB and STATs that participate in protein-
protein interaction with – and are modulated by – the GR;
47-49
 the lncRNA GAS5 which acts as a decoy 
GRE to riborepress the GR;
50
 and chromatin architecture.
51
 
CS are undoubtedly highly effective immunosuppressive agents that assist recovery in a range of 
pathologies. However, we consider that elucidation of the mechanisms of adverse effects of CS based 
immunotherapies is essential given the intimate relationship between myelination and axonal 
function/survival. For example, axons produce aberrant branches without the inhibitory effects of myelin.
52
 
The ordered arrangement of ion channels at the nodes of Ranvier (and therefore conductive properties of 
axons) also critically depends on correct myelination.
53
 Oligodendrocytes are considered to be essential to 
long-term axonal integrity, potentially through trophic support mechanisms and axon-glia metabolic 
coupling mechanisms
54,55
 leading to a widely held view that axon-myelin interactions have an important 
neuroprotective role (and by extension impact disease progression when perturbed).
16
 Consequently, CS-
induced delays in myelination are of significant clinical importance when considering treatment of a range 
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of paediatric and adult pathologies. Our findings demonstrate that OL lineage cells show limited responses 
to CS and are therefore not likely to constitute the direct cellular targets of CS action in the CNS. This is a 
somewhat unexpected finding, given that both OPCs and oligodendrocytes are key players in the process of 
myelin genesis.  
However, the exact mechanisms by which microglia impact myelin production in vivo are not fully resolved. 
Our pathway analyses do not indicate specific mechanisms by which microglial gene expression changes 
may directly impact myelin genesis, however more complex secondary effects may account for CS-induced 
myelin perturbations in vivo. During regeneration, impaired remyelination following microglial suppression 
is likely due to impaired myelin debris clearance.
56
 Microglial roles in developmental myelination are less 
clear, however at least one study suggests that myelin synthesis can be stimulated by microglial cells,
57
 
through unknown secretory mechanisms. Further, it is established that microglia secrete several soluble 
mediators including those with key roles in the development of the oligodendroglial lineage, such as IGF-
1.
58,59
 The release of such mediators is the critical first step towards successful myelin regeneration, and it is 
feasible that similar mechanisms may be operational during developmental myelination,
56
 and therefore 
perturbed by immunosuppressive therapies. We also cannot exclude the possibility that CS effects on myelin 
production may simply be related to a decrease in microglial numbers, as reported previously. In vivo DEX 
treatment has been shown to elicit a decrease in microglial numbers, this effect being dependent on both the 
dose employed
60
 and the duration of treatment.
61
 However, systematic correlative analyses of CS-induced 
microglial depletion and the progression of developmental myelination have not been conducted so far. 
Microglia remove supernumerary neurons during development, but it is not clear whether they perform the 
same role for supernumerary oligodendroglial cells (which are known to be reduced by up to 50% during 
development). Depleted numbers of microglia, and/or microglial dysfunction could also impair removal of 
dead cells and regulation of glial population numbers, essential to establishing normal neuron:glia ratios and 
interactions during development.
62 
 
In light of these points, the following transcriptional changes in our study may be of relevance. Analysis of 
the combination of all transcriptional changes on cellular function using the Ingenuity Pathway analysis tool 
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showed (i) DEX-treatment resulted in altered expression of genes relating to ‘cell movement’ (including 
‘migration of microglia’), therefore CS-treated microglia may demonstrate an impaired ability to migrate 
towards and phagocytose cells/synapses and myelin debris. (ii) Microglial cytokine secretion can affect 
neural/glial specification
59
 and cytokines such as interleukin-2 (IL-2), whose gene expression was shown to 
be altered in our analyses, can exert toxic effects on oligodendrocytes and myelin. The consequences of such 
changes on global myelin genesis are as yet unknown. Future work will need to establish whether our in 
vitro findings can be extrapolated to lesions in vivo, where the complex, intercellular crosstalk in sites of 
pathology is maintained, and where the CS doses encountered by cells may be different to those employed in 
our study. Nevertheless, our findings can provide a basis for future investigations into the precise 
relationship between microglia, immune suppression and myelination.  
Summary 
A detailed understanding of the cellular and molecular mechanisms underpinning adverse effects of 
immunosuppressive drugs in the nervous system is critical to the development of better classes of 
therapeutic agents. Our findings indicate that CS effects on myelin genesis are not primarily mediated by 
oligodendrocyte lineage cells. Instead, the primary mediators of such effects could be the microglial or 
astrocytic cells. The role of cellular cross-talk between astrocytes and other neural cells during development 
and remyelination is well established.
14
 Further, while microglial interactions can impact regenerative 
processes,
24
 their role in neural development remains elusive. Evidence is gathering, however, that microglia 
play critical roles in the regulation of precursor cell numbers
63
 and development of cortical neurons;
64
 the 
impact that immunotherapies have in the context of repair and development is therefore an important issue 
and will require elucidation. The current experiments were conducted within a short timeframe in purified 
cultures to attempt to identify the primary/early targets of drug action in the response cascade. However, we 
cannot rule out the possibility that cellular response profiles may be different following prolonged CS 
exposure. Therefore, further investigations to identify downstream effectors/target cells will require 
proteomic/secretomic analyses of CS treated glial populations, at later time points and with longer 
exposures, all within experimental systems that allow for examination of neural cell cross-talk. Such work 
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can potentially offer evidence for an indirect mechanism of CS effects on myelin genesis via a 
microglial/astrocytic cell intermediary. This detailed understanding can provide information relevant to the 
development of novel therapeutic agents/immunotherapies that limit adverse effects of CS, along with 
refinements to the timing and dose of existing CS therapy.  
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Materials and methods 
The care and use of animals was in accordance with the Animals (Scientific Procedures) Act of 1986 
(United Kingdom) with approval by the local ethics committee. 
Reagents: Tissue culture materials were from Fisher Scientific (UK). Recombinant human platelet-derived 
growth factor (PDGF-AA) and basic fibroblast growth factor (FGF2) were from Peprotech (UK). 
Dexamethasone (DEX) 21-phosphate disodium (D4902; ≥97% pure), culture media and anti-biotin 
secondary antibodies [Cy3- or fluorescein isothiocyanate (FITC)-conjugated] were from Sigma-Aldrich 
(UK). All other secondary antibodies were from Jackson ImmunoResearch Laboratories Inc. (USA). 
Mounting medium [with 4’,6-diamidino-2-phenylindole (DAPI)] was from Vector Laboratories (UK). RQ1 
RNase-free DNase and DNA ladders were from Promega (UK), Immolase DNA polymerase was from 
Bioline (UK), specific primers were from MWG Operon (Germany), random hexamer primers, Superscript 
II reverse transcriptase and RNase OUT were from Invitrogen (UK). 
Cell cultures: Primary mixed glial cultures were prepared from dissociated cerebral cortices of Sprague-
Dawley rats at postnatal day 1 – 3 and glial populations were isolated by sequential rotary shaking 
procedures using well-established protocols.
65,66
 Briefly, microglia were derived first (200 rpm, 1 h) and 
plated at 6 x 10
4
 cells/cm
2
 in D10 medium [Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 2 mM glutaMAX-I, 1 mM sodium pyruvate, 50 U/ml penicillin, and 50 
µg/ml streptomycin]. OPCs were derived next (200 rpm, 18 h) and plated at 4.5 x 10
4
 cells/cm
2
 in OPC 
maintenance medium (OPC-MM: DMEM supplemented with 2 mM glutaMAX-I, 1 mM sodium pyruvate, 
10 nM biotin, 10 nM hydrocortisone, 30 nM sodium selenite, 50 µg/ml transferrin, 5 µg/ml insulin, 0.1% 
bovine serum albumin, 50 U/ml penicillin, 50 µg/ml streptomycin, 10 ng/ml PDGF-AA, and 10 ng/ml 
FGF2). Finally, after an additional shake (200 rpm, 18 h) to deplete residual OPCs, adherent astrocytes were 
trypsinized and plated at 4 x 10
4
 cells/cm
2
 in D10. To deplete microglia from OPC and astrocyte fractions, 
cells were transferred to non-tissue-culture grade petri dishes (to which microglia readily attach) and after 30 
min the unattached cells were collected. To establish oligodendrocyte cultures, OPC cultures were switched 
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to Sato differentiation medium [DMEM supplemented with 2 mM glutaMAX-I, 1 mM sodium pyruvate, 1x 
N2 supplement (5 µg/ml insulin; 20 nM progesterone; 100 µM putrescine; 30 nM selenium; 100 µg/ml 
transferrin), 30 nM thyroxine, 30 nM triiodothyronine, 50 U/ml penicillin, and 50 µg/ml streptomycin]. All 
cultures were incubated at 37°C in 5% CO2/95% humidified air. Cells were plated on poly-D-lysine (PDL) 
coated 6-well plates for microarray/RNA studies, or PDL-coated chamber slides or coverslips in 24-well 
plates for histological studies.  
DEX treatment of cultures: DEX is frequently employed in clinical practice,
8,11
 particularly for the 
treatment of respiratory distress syndrome,
9
 reduction of cerebral oedema associated with intracranial 
neoplasms,
67
 and following acute spinal cord injury.
10
 This drug was therefore selected for use in the 
experimental studies, and is reported to act almost exclusively on the GR.
68
 DEX was prepared in ethanol 
with the concentration verified spectrophotometrically (Genesys 10S UV-Vis spectrophotometer, 
ThermoScientific, USA) then diluted in appropriate culture medium to the indicated concentration; the final 
concentration of ethanol was 0.27% (v/v) at all doses and for vehicle controls. The drug doses used here 
have been frequently used with neural cells including for microarray analysis,
36,69
 validating their use in the 
current study. Further, CS treatment of microglia promotes apoptosis,
70
 providing a simple and effective 
measure of CS effects, making microglia suitable positive controls to validate the biological efficacy of the 
DEX doses selected. Table 1 summarizes the protocols and timings of DEX treatment for individual assays.  
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Table 1 Protocol timings for DEX treatment of glial cells 
Experiment Cell type 
Culture 
medium
1
 
[DEX] 
DEX 
application 
post-plating 
Period of DEX 
treatment 
Total 
culture 
period 
Processing at end 
of DEX treatment; 
immunostaining 
for cell markers
2
 
T
ra
n
s
c
ri
p
ti
o
n
a
l 
e
ff
e
c
ts
 o
f 
C
S
 
(m
ic
ro
a
rr
a
y
) 
Astrocyte D10 1 µM 24 h 48 h 3 d RNA extraction 
Microglia D10 1 µM 24 h 48 h 3 d RNA extraction 
OPC OPC-MM 1 µM 24 h 48 h 3 d RNA extraction 
OL 
24 h 
OPC-MM, 
then Sato 
1 µM 4 d 48 h 6 d RNA extraction 
C
S
 e
ff
e
c
ts
 o
n
 
p
ro
lif
e
ra
ti
o
n
/ 
d
if
fe
re
n
ti
a
ti
o
n
/ 
m
o
rp
h
o
lo
g
y
 
Microglia D10 
1 µM, 
100 µM 
24 h 3 d 4 d Histology; OX42 
OPC OPC-MM 
1 µM, 
100 µM 
24 h 3 d 4 d 
Histology; A2B5, 
NG2 
OPC/OL 
24 h 
OPC-MM, 
then Sato 
1 µM, 
100 µM 
24 h (applied 
in Sato) 
7 d; refreshed 
every 2-3 d 
8 d Histology; MBP 
G
R
 d
e
te
c
ti
o
n
 
Astrocyte D10 1 µM 3 d 30 min 3 d 
Histology; H300, 
BuGR2/GFAP 
Microglia D10 1 µM 3 d 30 min 3 d 
Histology; 
H300/Lectin 
OPC OPC-MM 1 µM 3 d 30 min 3 d 
Histology; 
H300/NG2 
OL 
24 h 
OPC-MM, 
then Sato 
1 µM 9 d 30 min 9 d 
Histology; 
H300/MBP 
O
lig
1
 d
e
te
c
ti
o
n
 
Microglia D10 1 µM 24 h 48 h 3 d 
Histology; 
Olig1/Lectin 
OPC OPC-MM 1 µM 24 h 48 h 3 d 
Histology; 
Olig1/NG2 
OL 
24 h 
OPC-MM, 
then Sato 
1 µM 7 d 48 h 9 d 
Histology; 
Olig1/MBP 
DEX = dexamethasone; GR = glucocorticoid receptor; OL = oligodendrocyte; OPC = oligodendrocyte precursor cell; 
1
see ‘methods, cell cultures’ for medium details; 
2
see Table 2 for antibody/marker details 
Histological analyses 
Immunocytochemistry: Cells were fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) 
[room temperature (RT); 30 min] and washed in PBS. Table 2 summarizes the antibodies used to detect 
specific cell types and the immunostaining protocols. Cells were blocked (RT; 30 min), incubated overnight 
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with primary antibody in blocking solution (4°C; simultaneous antibodies for double-staining), washed, 
blocked, incubated with the appropriate FITC- or Cy3-conjugated secondary antibody in blocking solution 
(1:200; RT; 2 h; simultaneous antibodies for double-staining), washed and mounted with the nuclear stain 
DAPI. As both H300 and GFAP require anti-rabbit secondary antibody, BuGR2 was used with GFAP to 
double-stain astrocytes. 
Table 2 Antibodies and immunostaining protocols 
Antibody Supplier Blocking solution in PBS Antibody 
concentration 
Mouse anti-A2B5, OPC marker Sigma-Aldrich, UK 5% serum 1:200 
BuGR2, mouse anti-GR Abcam, UK 5% serum, 0.3% Triton 1:100 
Rabbit anti-GFAP, astrocyte 
marker 
DakoCytomation, UK 5% serum, 0.3% Triton 1:500 
H300, rabbit anti-GR Santa Cruz Biotech, USA 5% serum, 0.3% Triton 1:100 
Lectin (Lycopersicon 
esculentum, biotin-conjugated), 
microglial marker 
Sigma-Aldrich, UK 5% serum 1:150 
Rat anti-MBP, oligodendrocyte 
marker 
Serotech Ltd., UK 5% serum, 0.3% Triton 1:200 
Rabbit anti-NG2, OPC marker Millipore, UK 5% serum 1:150 
Mouse anti-Olig1 Millipore, UK 5% serum, 0.1% Triton 1:200 
OX42 (mouse anti-Cd11b), 
microglial marker 
Serotech Ltd., UK 5% serum
1
 1:500 
GR = glucocorticoid receptor; OPC = oligodendrocyte precursor cell; PBS = phosphate buffered saline; Triton = 
Triton X-100; 
1
pre-permeabilised cells with 1% Triton in PBS, 20 min, room temperature 
Image analysis: Immunostained samples were imaged using fixed exposure settings on an Axio Scope A1 
fluorescence microscope (Carl Zeiss MicroImaging GmbH, Germany), and the images merged using 
Photoshop CS3 (version 10.0.1; Adobe, USA). Culture purity was assessed by scoring the coincidence of 
DAPI-stained nuclei with immunostaining for the appropriate cell marker, for a minimum of three 
micrographs and 100 nuclei per treatment condition. Simultaneously, nuclei were scored for pyknosis, 
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indicated by fragmented, intensely stained nuclei, as a measure of toxicity. For oligodendrocyte cultures, 
MBP
+
 cells were assigned a morphological score to semi-quantitatively assess extent of 
differentiation/maturation as follows: (1) few or no processes, (2) processed but displaying some bipolarity, 
(3) multiple processes with loss of bipolarity (displaying radial symmetry), (4) highly-processed and (5) 
dense and elaborate/flattened processes. 
To validate microarray findings regarding Olig1 expression (see Microarray analysis section), fluorescence 
micrographs of control and CS-treated microglia were converted to grayscale (Photoshop) and calibrated as 
a batch (optical density step-tablet, Rodbard equation; ImageJ, National Institutes of Health, USA). The 
relative expression of Olig1 protein was quantified using optical density measurements of individual cells 
(minimum of 30 lectin
+
 microglia and 3 images per condition per culture), with background readings 
subtracted.  
RNA analyses 
Total RNA extraction: For these experiments, microglia and astrocytes (from the same parent primary 
cultures as OPCs/oligodendrocytes) were used as positive controls. Both express the GR
71,72
 (providing RT-
PCR validation) and are CS responsive,
26,73,74
 so can be predicted to show significant alterations in gene 
expression, making both cell types suitable positive controls for microarray analysis. All cell types were 
washed with nuclease-free PBS then RNA was extracted using an RNeasy Mini Kit (Qiagen, UK), as per 
manufacturer’s instructions. Concentrations were determined by Nanodrop spectrophotometry (Labtech, 
UK) and samples stored at -80°C. 
RT-PCR: Residual genomic DNA from vehicle only samples was removed using RNase-free DNase then 
RNA was reverse transcribed using random hexamer primers and reverse transcriptase, all according to the 
manufacturer’s protocols. cDNA was amplified by hot-start RT-PCR with specific primers for GR
75
 (36 
cycles) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
76
 34 cycles). Products were 
electrophoresed on 2% agarose gels with 100 bp DNA ladders. Primer sequences were: 
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GR: fwd: 5’GAG CAG AGA ATG TCT CTA CCC; rev: 5’GAC GAT GGC TTT TCC TAG CTC. 
GAPDH: fwd: 5’ACC ACA GTC CAT GCC ATC AC; rev: 5’TCC ACC ACC CTG TTG CTG TA. 
Microarray analysis: For each cell type, RNA samples from four cultures were dispatched to Source 
Bioscience UK Ltd. (Nottingham, UK) for processing and hybridisation. RNA integrity was determined 
using the Bioanalyzer (Agilent, USA) and the three pairs of RNA samples (DEX treated and vehicle only 
control samples from the same culture) with the highest quality per condition were selected for microarray 
analysis. 750 ng of processed cRNA was hybridized to Illumina RatRef-12 bead chips. Differentially 
expressed genes were identified using limma package of R.
77
 Data was normalized using the neqc function 
of the limma package found to be robust for Beadarray analysis.
78
 Beads with quality scores (detection 
probability) < 95% in any sample were removed, resulting in 15,498 genes analyzed. Significantly 
differentially-expressed genes were identified using a modified t-test with Benjamini-Hochberg test to 
control false discovery rate (FDR) for multiple testing. Genes were considered as differentially-expressed if 
corrected p values were < 0.05 and log2 fold change values were ≥ |1|. Enrichment and Pathway analysis 
was conducted using the MetaCore™ platform, with all genes reported here having an enrichment FDR 
corrected p value < 0.01 and a minimum of two genes in an enriched category. One transcriptionally-altered 
gene (Olig1) was selected in order to validate the microarray findings by double-immunostaining microglia 
for both lectin and Olig1, using OPCs (NG2 staining) and oligodendrocytes (MBP staining) as positive 
controls as Olig1 expression is considered to be restricted to oligodendrocyte lineage cells.
38
  
Statistical analysis: Other than for the array analysis described above, data were analyzed using Prism 
statistical analysis software (GraphPad, USA). All data are expressed as mean ± SEM. The number of 
experiments (n) refers to the number of mixed glial cultures from which isolated cultures were derived, with 
each primary culture being established from a different rat litter. For CS effects on oligodendroglia and 
microglia, data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-tests for 
post-hoc analysis. Optical density measurements of Olig1 expression were averaged for each 
culture/condition, normalized then analyzed by a paired t-test. 
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Supporting information available: Microarray analyses are provided as Excel files. 
Gene.lists.with.annotations; Astrocyte.Enrichment_Analysis; Mglia.Enrichment_Analysis; 
Oligo.Enrichment_Analysis; OPC.Enrichment_Analysis. The complete microarray dataset has been 
deposited at ArrayExpress (Experiment name: Corticosteroid treatment of glial cell types; ArrayExpress 
accession: E-MTAB-1695). This material is available free of charge via the Internet at http://pubs.acs.org. 
Abbreviations: CNS, central nervous system; CS, corticosteroid; DEX, dexamethasone; GFAP, glial 
fibrillary acidic protein; GR, glucocorticoid receptor; MBP, myelin basic protein; OPC, oligodendrocyte 
precursor cell. 
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